Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
Drug resistance: Overcoming localized resistance to anti-HER2 therapy Location-specific subpopulations of breast cancer cells adapt to targeted drug treatment, but therapeutic strategies exist to attack these niche-protected cells. A team led by Joan Brugge and Jason Zoeller from Harvard Medical Sch...
Guardado en:
Autores principales: | Jason J. Zoeller, Roderick T. Bronson, Laura M. Selfors, Gordon B. Mills, Joan S. Brugge |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e1b922c7c04a43b2995e897f3abba5b9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
por: Jason J Zoeller, et al.
Publicado: (2021) -
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
por: Ioannis K. Zervantonakis, et al.
Publicado: (2017) -
α7 nicotinic acetylcholine receptor upregulation by anti-apoptotic Bcl-2 proteins
por: G. Brent Dawe, et al.
Publicado: (2019) -
Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
por: Armando Bartolazzi, et al.
Publicado: (2008) -
Liquiritigenin-Loaded Submicron Emulsion Protects Against Doxorubicin-Induced Cardiotoxicity via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Activity
por: Shi C, et al.
Publicado: (2020)